Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin as an Antihypertensive Agent
NCT05679102Completed
- Start
- Dec 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of atorvastatin in hypertension (HTN) (2 arms). Primary endpoint: Antihypertensive effect of atorvastatin at 14 days. Started Dec 2022; status: completed.
02
Drugs
atorvastatin
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05679102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05679102.